Pharmerging Markets 2016-2020 - Leading Vendors are AstraZeneca, GlaxoSmithKline, Merck, Novartis, Pfizer & Sanofi

Dec 11, 2015, 06:10 ET from Research and Markets

DUBLIN, Dec. 11, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/hs23s6/pharmerging) has announced the addition of the "Pharmerging Markets 2016-2020" report to their offering.

Pharmerging countries mostly include developing or less-developed countries where the affordability of drugs plays a major role for the blossoming of the market. Hence, the utilization and sale of generic drugs are high. Though the sales of generics have slowed down, the sales still outpace the sales of originator molecules. Also, pharmaceutical companies such as Pfizer and Sanofi are showing an interest toward the development of generics for attaining considerable shares in the pharmerging markets.

According to the report, public and private healthcare insurance are among the major drivers influencing the growth of this market. The governments of pharmerging countries such as India have implemented schemes that can be availed by eligible patients to obtain free treatment for diseases.

Further, the report states that poor access to and affordability of drugs challenge pharmerging markets.

Key questions answered in the report include:

  • What will the market size and the growth rate be in 2020
  • What are the key factors driving the pharmerging markets
  • What are the key market trends impacting the growth of the pharmerging markets
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the vendors in the pharmerging markets
  • Trending factors influencing the market shares of Tier I, Tier II, and Tier III countries
  • What are the key outcomes of the five forces analysis of the pharmerging markets

The leading vendors in the market are -

  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Sanofi

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Global pharmaceuticals market

PART 06: Pharmerging markets

PART 07: Market landscape

PART 08: Market segmentation based on geography

PART 09: Market overview of Tier I countries

PART 10: Market overview of Tier II countries

PART 11: Market overview of Tier III countries

PART 12: Market drivers

PART 13: Impact of drivers

PART 14: Market challenges

PART 15: Impact of drivers and challenges

PART 16: Market trends

PART 17: Vendor landscape

20 of 45+ Companies Mentioned:

  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Sanofi
  • Abbott Laboratories
  • AbbVie
  • Alexion Pharmaceuticals
  • Allergan
  • Amgen
  • Aspen
  • Astellas Pharma
  • Baxter
  • Bayer
  • Biogen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Chugai Pharmaceutical

For more information visit http://www.researchandmarkets.com/research/hs23s6/pharmerging

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net

 

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com